Full Text
Cost-Effectiveness of Saxagliptin Versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China

Abstract

Authors

S Gu H Shao Y Zeng L Shi H Dong

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×